Literature DB >> 8069025

Separation between ischemic and reperfusion injury by site specific entrapment of endogenous adenosine and inosine using NBMPR and EHNA.

A S Abd-Elfattah1, A S Wechsler.   

Abstract

BACKGROUND: Although myocardial ATP is essential for myocardial viability and ventricular function, it is a major source of free radical substrates for endothelial xanthine oxidase. Correlation between myocardial ATP and ventricular function has been hindered by the impact of ATP catabolites on ventricular function during reperfusion.
OBJECTIVES: This work results from four separate experiments assessing the role of nucleoside efflux in reperfusion mediated injury to determine the dual role of myocardial ATP in postischemic ventricular dysfunction. An adenosine deaminase inhibitor, erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), and an adenine nucleoside transport blocker, p-nitrobenzylthioinosine (NBMPR), were used to specifically inhibit adenosine deamination and block nucleoside release, respectively. This pharmacological intervention results in site-specific entrapment of intramyocardial adenosine and inosine, generated during ischemia, and blocks degradation to free radical substrates during reperfusion, thereby limiting the impact of reperfusion mediated injury.
METHODS: Forty-three anesthetized dogs were instrumented to monitor left ventricular performance from the slope of the relationship between stroke work and end-diastolic length (SW/EDL). Hearts were subjected to varying periods (30, 60, or 90 min) of global ischemia and 60 or 120 minutes of reperfusion. Two control groups for 30 and 60 minutes of ischemia (16 dogs) received only saline solution. Four treated groups (27 dogs) received saline containing 100 microM EHNA and 25 mM NBMPR prior to ischemia or only during reperfusion (n = 7). Myocardial biopsies were analyzed for ATP catabolites and NAD+.
RESULTS: Myocardial ATP and left ventricular function were severely depressed by 50% and 80% in the untreated controls, following 30 and 60 minutes of ischemia (37 degrees C), respectively. Ventricular dysfunction was inversely related to inosine levels in the myocardium at the end of the ischemic period. Administration of EHNA/NBMPR before ischemia or only during reperfusion resulted in significant accumulation of mainly adenosine or inosine, respectively. Entrapment of nucleosides was associated with complete recovery of ventricular function after 30 or 60 minutes of ischemia. Hearts subjected to 90 minutes of ischemia developed contracture.
CONCLUSIONS: Despite severely reduced ATP levels, ventricular function significantly recovered to preischemic values only in the EHNA/NBMPR-treated groups. Selective blockade of purine release during reperfusion is cardioprotective against post-ischemic reperfusion mediated injury. It is concluded that nucleoside transport plays an important role in regulation of endogenous adenosine and inosine affecting the degree of myocardial injury or protection from reperfusion mediated injury.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8069025     DOI: 10.1111/jocs.1994.9.3s.387

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  8 in total

1.  Differential cardioprotection with selective inhibitors of adenosine metabolism and transport: role of purine release in ischemic and reperfusion injury.

Authors:  A S Abd-Elfattah; M E Jessen; J Lekven; A S Wechsler
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

2.  Identification of nucleoside transport binding sites in the human myocardium.

Authors:  A S Abd-Elfattah; J Hoehner; A S Wechsler
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

3.  Effects of nucleoside transport inhibitors and adenine/ribose supply on ATP concentration and adenosine production in cardiac myocytes.

Authors:  K K Kalsi; R T Smolenski; M H Yacoub
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

4.  Purine metabolism and release during cardioprotection with hyperkalemia and hypothermia.

Authors:  Hajime Imura; Ben E Ayres; M Saadeh Suleiman
Journal:  Mol Cell Biochem       Date:  2002-08       Impact factor: 3.396

5.  Hot shot induction and reperfusion with a specific blocker of the es-ENT1 nucleoside transporter before and after hypothermic cardioplegia abolishes myocardial stunning in acutely ischemic hearts despite metabolic derangement: hot shot drug delivery before hypothermic cardioplegia.

Authors:  Anwar Saad Abd-Elfattah; Gert E Tuchy; Michael E Jessen; David R Salter; Jacques P Goldstein; Louis A Brunsting; Andrew S Wechsler
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02-17       Impact factor: 5.209

6.  Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity.

Authors:  Zhengxiang Zhu; John K Buolamwini
Journal:  Bioorg Med Chem       Date:  2008-01-30       Impact factor: 3.641

7.  Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors.

Authors:  Wenwei Lin; John K Buolamwini
Journal:  J Med Chem       Date:  2007-07-18       Impact factor: 7.446

8.  Label-free detection of transporter activity via GPCR signalling in living cells: A case for SLC29A1, the equilibrative nucleoside transporter 1.

Authors:  Anna Vlachodimou; Adriaan P IJzerman; Laura H Heitman
Journal:  Sci Rep       Date:  2019-09-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.